SEARCH

SEARCH BY CITATION

References

  • 1
    Knoll Pharmaceutical Co. (2000) Meridia (sibutramine hydrochloride monohydrate). Prescribing information. In: Physician's Desk Reference Montvale, NJ: Drug Information Services Group; pp. 150913.
  • 2
    Roche Laboratories. (2000) Xenical (orlistat). Prescribing information. In: Physician's Desk Reference Montvale, NJ: Drug Information Services Group; pp. 26936.
  • 3
    Lean, M. E. J. (1997) Sibutramine: a review of clinical efficacy. Int J Obes 21: 30S36S.
  • 4
    Davidson, M. H., Hauptman, J., DiGirolamo, M., et al. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281: 235242.
  • 5
    Heymsfield, S. B., Segal, K. R., Hauptman, J., et al. (2000) Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Int Med 160: 13211326.
  • 6
    Sjöström, L., Rissanen, A., Anderson, T., et al. (1998) Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352: 167173.
  • 7
    Foster, G. D., Wadden, T. A., Vogt, R. A. (1997) What is a reasonable weight loss?: patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 65: 7985.
  • 8
    Bray, G. A., Greenway, F. L. (2000) Current and potential drugs for treatment of obesity. Endocr Rev 20: 805875.
  • 9
    Atkinson, R. L., Blank, R. C., Schumacher, D., Dhurandhar, N. V., Ritch, D. L. (1997) Long-term drug treatment of obesity in a private practice setting. Obes Res 5: 578586.
  • 10
    Weintraub, M., Sundaresan, P. R., Madan, M., et al. (1992) Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 51: 586594.
  • 11
    Wadden, T. A., Berkowitz, R. I. Sarwer, D. B., Prus-Wisniewski, R., Steinberg, C. M.. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.. Arch Int Med. in press.
  • 12
    Wadden, T. A., Sarwer, D. B., Berkowitz, R. I. (1999) Behavioral treatment of the overweight patient. Bailliere's Clin Endocrin Metab 13: 93107.
  • 13
    Brownell, K. D. (2000) The Learn Program for Weight Management 2000 209210. American Health Publishing Co Dallas, TX.
  • 14
    Ravussin, E., Swinburn, B. A. (1992) Effect of caloric restriction and weight loss on energy expenditure Wadden, TA VanItallie, TB eds. Treatment of the Seriously Obese Patient 163189.Guilford Press New York.
  • 15
    Campfield, L. A., Smith, F. J., Burn, P. (1996) The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. J Metab Res 28: 619632.
  • 16
    Stunkard, A. J. (1982) Mini review: anorectic agents lower a body weight set point. Life Sci 30: 20432055.
  • 17
    Andersen, T., Astrup, A., Quaade, F. (1992) Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. Int J Obes 16: 3540.
  • 18
    Wadden, T. A., Foster, G. D., Letizia, K. A. (1994) One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of maintenance therapy. J Consult Clin Psychol 62: 165171.
  • 19
    Andersen, T., Astrup, A., Quaade, F. (1992) Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. Int J Obes 16: 3540.
  • 20
    Hill, J. O., Hauptman, J., Anderson, J. W., et al. (1999) Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 69: 11081116.
  • 21
    Connolly, H. M., Crary, J. L., McGoon, M. D., et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581588.
  • 22
    Brownell, K. D., Stunkard, A. J. (1982) The double-blind in danger: untoward consequences of informed consent. Am J Psychiatry 139: 14871489.